510 hasil
Menampilkan 1–20 · 0,64 detik · RSS
Leukemia Research Reports
Scopus
ISSN 2213-0489 · Elsevier · 510 artikel di indeks
-
Artikel Jurnal
Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma
Introduction: A combination of Gemcitabine, Dexamethasone and Cisplatin (GDP) with or without rituximab (±R) is an outpatient treatment widely used for relapsed or refractory (R/R) lymphoma. Limited data are available on stem cell mobilization following GDP treatment. Method: A retrospective…
-
Artikel Jurnal
Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report
Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy. Richter transformation is the transformation of CLL/SLL into an aggressive lymphoma, typically necessitating…
-
Artikel Jurnal
Acute liver failure and severe lactic acidosis as initial manifestations of primary intestinal diffuse large B-cell lymphoma: Case report
Diffuse large B-cell lymphoma (DLBCL) typically presents with lymphadenopathy or extranodal masses, but rarely, predominantly as scattered case reports, as acute liver failure (ALF) with severe lactic acidosis. We report a 79-year-old man who presented with fulminant ALF, leukemoid reaction, and…
-
Artikel Jurnal
Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up
Secondary pure red cell aplasia (PRCA) is one of the most common cytopenic complications in T-cell large granular lymphocyte (T-LGL) leukemia and requires therapeutic intervention. Refractory T-LGL-associated PRCA lacks a unified salvage regimen, and effective targeted agents remain scarce. In…
-
Artikel Jurnal
Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study
Background: Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging, and achieving metabolic complete response prior to autologous stem cell transplantation (ASCT) is important. GDP is a generally well-tolerated outpatient regimen, while brentuximab vedotin (BV) has…
-
Artikel Jurnal
Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An indian experience
Background: Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and comprises 9 % of total NHL in India. Rituximab maintenance (RM) after induction immunochemotherapy improves PFS. However, currently, no data exists from the Indian continent regarding the impact…
-
Artikel Jurnal
A rare case of variant acute promyelocytic leukemia with FIP1L1-RARA fusion gene: case report and literature review
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) fusion gene and exceptional responsiveness to differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide…
-
Artikel Jurnal
Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam
Objective: Hematopoietic stem cell transplantation (HSCT) is an effective treatment for acute myeloid leukemia (AML) patients, leveraging cytotoxic conditioning regimens and graft-versus-leukemia effects. Reduced-intensity conditioning (RIC) regimens extend this therapy to elderly patients and…
-
Artikel Jurnal
Gilteritinib-associated hand-foot syndrome: a novel dermatologic reaction in refractory FLT3 Acute myeloid leukemia
Objective: Second generation tyrosine kinase inhibitors (TKIs) such as gilteritinib, characterized by minimal EGFR and absent VEGFR inhibition, are in theory associated with low dermatologic toxicity. This case report brings to the awareness that the opposite may occur and emphasize the need for…
-
Artikel Jurnal
Multidisciplinary approaches to coexisting Glanzmann thrombasthenia and juvenile polyposis syndrome
Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding disorder from defects in the αIIbβ3 integrin receptor, impairing platelet aggregation and often overlooked due to normal platelet counts. Juvenile polyposis syndrome (JPS) is an autosomal dominant disorder with multiple…
-
Artikel Jurnal
The role of RAS mutations in leukemia progression, differentiation, and drug resistance
Mutations in the RAS gene family (NRAS, KRAS) are critical drivers of late-stage acute myeloid leukemia (AML) progression. They are frequently detected in relapsed/refractory AML and AML transformed from myelodysplastic syndrome (MDS). Occurring as late-stage genetic events, RAS mutations synergize…
-
Artikel Jurnal
Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country
Background: Hypomethylating agents such as decitabine represent a key treatment option for elderly acute myeloid leukemia (AML) patients who are unfit for intensive chemotherapy. However, real-world evidence from low- and middle-income countries (LMICs), including Vietnam, remains scarce. This…
-
Artikel Jurnal
Meta-analysis of clinical efficacy and safety of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly
Objective: To systematically evaluate the clinical efficacy and safety of decitabine (DAC) combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia (AML) using meta-analysis Methods: The studies reported the clinical efficacy and safety of DAC combined with CAG…
-
Artikel Jurnal
The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia
Objective: The objective of this research is to explore the anti-leukemic properties of CDK4/6 inhibitors when used alongside BET inhibitors for treating acute myeloid leukemia (AML), as well as to clarify the molecular mechanisms involved. Methods: Cell viability was assessed using the CCK-8 assay…
-
Artikel Jurnal
Pancreatitis induced by Peg-aspargase in children: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
This study analyzed FAERS data to evaluate pegaspargase safety in pediatric acute lymphoblastic leukemia treatment. Among 21,161,817 reports, 847 identified pegaspargase as the primary suspect drug, revealing adverse events (AEs) across 26 organ systems. Disproportionality analysis identified four…
-
Artikel Jurnal
Imatinib-induced rhabdomyolysis: A case report
Imatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), is associated with myalgia and creatine kinase (CK) elevations, though severe rhabdomyolysis and myopathy are rare. We report an 83-year-old woman with CML who developed…
-
Artikel Jurnal
Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter’s syndrome
Richter’s syndrome (RS) is characterized by transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma. While significant treatment advances have been made in the management of CLL/SLL, current front-line management of RS is consistent with…
-
Artikel Jurnal
Leukocytosis and a JAK2 mutation: The importance of expertise in somatic variant interpretation
This case details a patient presenting with a history of chronic leukocytosis with isolated eosinophilia, who was found to have a JAK2 G571S mutation by a next generation sequencing (NGS) panel for myeloproliferative neoplasm driver mutations. Adjunct NGS testing was performed on a sample of buccal…
-
Artikel Jurnal
When the mask slips: A peripheral T-cell lymphoma disguised as lupus with myelofibrosis in a patient with May-Hegglin syndrome
We describe the case of a female patient with May-Hegglin syndrome who developed peripheral T-cell lymphoma not otherwise specified. The patient presents with systemic lupus erythematous phenotype and myelofibrosis secondary to T-cell lymphoma. Peripheral T-cell lymphoma not otherwise specified…